226249-01-0Relevant academic research and scientific papers
Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series
Moree, Wilna J.,Kataoka, Ken-ichiro,Ramirez-Weinhouse, Michele M.,Shiota, Tatsuki,Imai, Minoru,Tsutsumi, Takaharu,Sudo, Masaki,Endo, Noriaki,Muroga, Yumiko,Hada, Takahiko,Fanning, Dewey,Saunders, John,Kato, Yoshinori,Myers, Peter L.,Tarby, Christine M.
, p. 1869 - 1873 (2008/09/19)
SAR studies were conducted around lead compound 1 using high-throughput parallel solution and solid phase synthesis. Our lead optimization efforts led to the identification of several CCR2b antagonists with potent activity in both binding and functional a
Novel compounds
-
, (2008/06/13)
The invention provides compounds of general formula (I) wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
REMEDIES OR PREVENTIVES FOR DISEASES IN ASSOCIATION WITH CHEMOKINES
-
, (2008/06/13)
This invention provides remedies or prophylactics for diseases in association with chemokines such as MIP-1 α and/or MCP-1. Namely, remedies or prophylactics for diseases in association with the chemokines such as rheumatoid arthritis or nephritis contain
CYCLIC AMINE CCR3 ANTAGONISTS
-
, (2008/06/13)
A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1 to C6 alkyl addition sal
